

ASX ANNOUNCEMENT | 25 JUNE 2026

IBX Secures Firm Commitments for \$3.75m To Fund Clinical Trial Commencement

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through early and more accurate detection of cancers using its proprietary MagSense® molecular imaging technology, is pleased to announce the Company has received \$3.75 million of firm commitments under a strongly supported capital raising.

This capital raising was led by CPS Capital Group Pty Ltd (**CPS Capital**), as a placement of ordinary shares to Australian sophisticated investors and family offices raising \$3.75m following the recently announced clearance by the FDA of the Company's Investigational New Drug (IND) application. The proceeds will be used to fund the commencement of the MagSense® HER2 imaging agent Phase 1b/2 clinical trial across multiple sites in the USA.

IBX Executive Chairman, Robert Proulx commented, "We are very pleased with the strong demand we saw from investors following our milestone achievement receiving clearance from the FDA for our MagSense® imaging to proceed with the clinical trial. The successful submission of the IND represents a major technical and organisational accomplishment for the company being recognised by our shareholders and the markets. With this kind of shareholder support we can continue to advance our MagSense® molecular imaging technology and change how cancer is detected. I want to thank CPS Capital for their lead role and all the investors who have shown their support."

Details of \$3.75m Capital Raising

The Company will raise \$3.75m of new capital (before costs) through a 2-tranche placement of new fully paid ordinary shares (**New Shares**) to sophisticated professional investors, with each investor in the placement to receive one free attaching IBXO listed option (**Listed Options**) for every two New Shares acquired (**Placement**). The Placement was managed by CPS Capital (**Broker and Lead Manager**), with support from investors exceeding expectations.

The issue price for the Placement was \$0.012 per New Share. The Listed Options will be issued under the same terms as the Company's existing listed options (IBXO), exercisable at \$0.04 per listed option and expire on 13 December 2027. The offer price of the New Shares represents a 24.32% discount to the 10-day volume-weighted average price (VWAP) before the date the capital raising was announced.

The Directors and management have agreed to subscribe for New Shares up to the value of \$100,000 of as part of the capital raising on the same terms and conditions, subject to shareholder approval at an Extraordinary General Meeting (EGM), expected to be held in August 2026.

The Placement will comprise of two tranches:

- Tranche 1: Placement of 49.3 million new shares at \$0.012 per New Share to raise approximately \$592,000 utilising the Company’s existing placement capacity under ASX Listing Rule 7.1, and
- Tranche 2: The issue of the balance of shares, representing a value of approximately \$3.2 million, is conditional upon the Company obtaining shareholder approval at an EGM.

A resolution to approve the issue of the free attaching New Listed Options attributable to both tranches will also be put to shareholders at the EGM.


The Broker and Lead Manager is to receive a capital raising fee of 4% and a 2% management fee on the gross proceeds received from the Placement. CPS Capital will also receive a tranche of 30,000,000 IBXO listed options (**Lead Manager Options**). The Lead Manager Options are to be approved by shareholders at the EGM.

Use of Proceeds

Placement funds will be used primarily to fund the start of the Phase 1b/2 Clinical Trial in HER2+ Breast Cancer. The Company has commenced trial activation activities for its HER2 Breast Cancer Phase 1b/2 clinical trial, and expects patient recruitment to begin later in Q3 of this year. Key activities include:

- The initiation of the clinical trial and completion of the first cohort of patients;
- On-going drug manufacturing activities of the MagSense® imaging agent to support clinical development;
- Development of Intellectual Property (IP) related to molecular MRI; and
- Collaborations with leading MRI experts to further develop quantitative MRI techniques and AI-based modelling optimised for the MagSense® imaging technology.

As previously disclosed, the trial consists of multiple parts as shown in the below scheme. The Company anticipates progress over the near term to include, commencement of enrolment, first patient dosed, and completion of the first cohort of participants.



Indicative Timetable

The settlement of the Tranche 1 is expected to occur on Monday, 29 June 2026 and allotment and normal trading of New Shares under Tranche 1 is expected to occur on Tuesday, 30 June 2026.

Trading halt lifted, and shares recommence trading on ASX	Thursday, 25 June 2026
Settlement of Tranche 1	Monday, 29 June 2026
Allotment and normal trading of New Shares under Tranche 1	Tuesday, 30 June 2026
General Meeting	August 2026
Settlement, allotment and normal trading of New Shares under Tranche 2 and New Listed Options under Tranche 1 & 2	August 2026 – Soon after the approval of shareholder is received at the General Meeting

The timetable is indicative only and remains subject to change at the Company’s discretion, subject to compliance with applicable laws and the ASX Listing Rules. The Company reserves the right to change the timetable at any time before New Shares and New Options are issued, subject to regulatory requirements.

All New Shares and New Listed Options issued under the Placement will rank equally with existing shares and listed options on issue. An Appendix 3B for the proposed issue of securities will follow this announcement.

Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

-END-

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com.

Executive Chairman Contact Details

Bob Proulx
investor@imagonbio.com
AU: +61 3 9692 7222

Media Enquiries & Investor Relations

Erich Boileau, Boileau & Co.
imagonbio@boileau.co
US : +1 (616) 786-4461